The FVC/DLCO Ratio is a Useful Predictor of Pulmonary Hypertension in Patients With Interstitial Lung Disease

Completed

• Conditions: Interstitial Lung Disease; Pulmonary Hypertension

• Registration Number: NCT03396120
• Lead Sponsor: Assiut University

Brief Summary

Pulmonary hypertension (PH) is a common disorder among patients with interstitial lung disease (ILD). The symptoms are usually nonspecific and overlooked. Thus, a noninvasive screening modality is recommended for early detection of PH because of its potentially significant impact on treatment strategy and clinical outcomes.

Objectives: To evaluate the usefulness of assessing forced vital capacity (FVC%), diffusion capacity of the lung for carbon monoxide (DLCO%), and FVC%/DLCO% ratio to predict pulmonary hypertension among patients with ILDs.

Detailed Description

Not available

Study Timeline

• Study Start: 2017-02-02
• Primary Completion: 2017-12-01
• Study Completion: 2017-12-31
• Status Verified: 2018-01
• Study First Submitted: 2018-01-05
• Study First Submitted QC: 2018-01-05
• Last Update Submitted: 2018-01-05
• Study First Posted: 2018-01-10
• Last Update Posted: 2018-01-10

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 95

Inclusion Criteria

• This retrospective study included all patients diagnosed with interstitial lung disease (ILD) who were followed up by the chest department of a tertiary hospital between September 2016 and January 2017

Read More

Exclusion Criteria

• patients with occupational history
• collagen vascular disease predisposing them to lung disorders
• patients who could not undergo pulmonary function testing

Read More

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
value of FVC/DLCO in predicting PAH in IPF	6 months	To evaluate the usefulness of assessing forced vital capacity (FVC%), diffusion capacity of the lung for carbon monoxide (DLCO%), and FVC%/DLCO% ratio to predict pulmonary hypertension among patients with ILDs

Trial Locations

Locations (2)

AssiutU; 🇪🇬 Assiut, Egypt

Pulmonology Departments; 🇪🇬 Assiut, Egypt